Novo Nordisk
-
Insulin affordability in focus: Novo Nordisk and Eli Lilly lower prices in the US
USA — Novo Nordisk has followed in the footsteps of Eli Lilly by announcing a reduction in the prices of its insulin products in the…
-
EMA issues warning on Ozempic shortage and potential risks for diabetes patients
NETHERLANDS — The European Medicines Agency (EMA) has urged doctors to prioritize the diabetes drug Ozempic, manufactured by Novo Nordisk, for patients with diabetes who…
-
Former Novo Nordisk vice chair to step down
DENMARK — Novo Nordisk has announced that Jeppe Christiansen will not stand for re-election as member of the Board at the AGM to be held…
-
Novo Nordisk celebrates 100th global anniversary in India, to launch a once-a-week insulin shot
INDIA – Danish pharma giant Novo Nordisk has celebrated its 100th global anniversary with a special event in Bangalore, India. The major milestone comes at…
-
Novo Nordisk apologizes for undisclosed sponsorship of anti-obesity training
DENMARK — Novo Nordisk’s CEO has apologized for breaching the UK industry code by not disclosing its sponsorship of obesity and weight management courses for…
-
ABPI president steps down over Novo Nordisk breach of trade group’s code
UNITED KINGDOM —The president of the Association of the British Pharmaceutical Industry (ABPI) and UK head of Novo Nordisk, Pinder Sahota, has resigned from the…
-
FDA approves Novo Nordisk’s diabetes pill as first-line therapy
USA — The US Food and Drug Administration (FDA) has approved a label update for Novo Nordisk’s oral semaglutide (Rybelsus) allowing the agent to be…
-
Novo Nordisk expands partnership with Amalgam Rx on connected insulin delivery devices
DENMARK —Novo Nordisk has expanded its collaboration with Amalgam Rx, a US-based company to support the commercialization of Dose Check, a digital insulin initiation and…
-
Novo Nordisk invests US$743M to expand clinical manufacturing facilities
DENMARK — Danish pharmaceutical company Novo Nordisk is set to invest 5.4 billion Danish kroner (US$743.6 million) in expanding its facilities in Bagsvaerd, Denmark, which…
-
Novo Nordisk signs commercialization pact with Biocorp for insulin delivery accessory
DENMARK — Novo Nordisk has signed a collaboration agreement with Biocorp for the initial commercialization of Mallya, initially in Japan. Mallya connects directly to Novo…